COMPLETE GENOMICS, INC. 
By Aug 24, 2011
MOUNTAIN VIEW, Calif. — Aug 24, 2011 — Complete Genomics Inc. (NASDAQ: GNOM), the complete human genome sequencing company, today announced additional details about the option that SAIC-Frederick Inc. has exercised to have Complete Genomics sequence the DNA from more than 500 pediatric cancer cases. This project was first announced during Complete Genomics’ Q2 earnings call on Aug. 4, 2011. Each case consists of a tumor-normal pair, and some cases include a relapsed tumor. This additional study follows the first phase of the project in which Complete Genomics sequenced and analyzed 100 genomes (50 tumor-normal pairs) from pediatric cancer cases on behalf of SAIC-Frederick Inc., which is the prime contractor for the NCI’s R&D facility in Frederick, Md., under contract HHSN261200800001E.
The goal of this ongoing study is to identify and verify somatic mutations. The project is part of the NCI’s Therapeutically Applicable Research to Generate Effective Treatments (TARGET) Initiative, which seeks to use genomics technologies to rapidly identify valid therapeutic targets in childhood cancers so new, more effective treatments can be developed. The initial pilot study focused on five childhood cancers: acute lymphoblastic leukemia, acute myeloid leukemia, neuroblastoma, osteosarcoma and Wilms tumor.
“We are delighted to have expanded our relationship with SAIC-Frederick and the NCI, who will be leveraging our complete human genome sequencing and analysis service to help identify possible genetic mutations and markers for childhood cancers,” said Dr. Clifford Reid, chairman, president and CEO of Complete Genomics. “We believe that the TARGET Initiative has the potential to help researchers accelerate the development of viable therapies to treat and prevent the most common childhood cancers and reduce the more than 10,000 new pediatric cancer diagnoses each year.”
In this phase of the collaboration, Complete Genomics is focusing on identifying somatic mutations associated with specific tumor types, and the resulting research-ready data will be submitted to the TARGET Database, where it will be a resource for NCI researchers.
Complete Genomics will be paid more than $8 million for completing this phase of the project, which is funded by the American Recovery and Reinvestment Act of 2009.
About Complete Genomics
Complete Genomics is a complete human genome sequencing company that has developed and commercialized an innovative DNA sequencing platform. The Complete Genomics Analysis Platform (CGA™ Platform) combines Complete Genomics’ proprietary human genome sequencing technology with our advanced informatics and data management software. The innovative, end-to-end, outsourced CGA™ Service provides customers with data ready for genome-based research. Additional information can be found at http://www.completegenomics.com.
Forward-Looking Statements
Certain statements in this press release, including statements relating to the ability of scientists to use the genome sequencing data that we provide to them to help identify possible genetic mutations and markers for childhood cancers and to accelerate the development of viable therapies to treat and prevent the most common childhood cancers are forward-looking statements that are subject to risks and uncertainties. Readers are cautioned that these forward-looking statements are based on management’s current expectations, and actual results may differ materially from those projected. The following factors, without limitation, could cause actual results to differ materially from those in the forward-looking statements: the ability of scientists to successfully analyze the genomic data we provide; and the ability of researchers to convert genomic data into medically valuable information. More information on potential risks and uncertainties is included in our Securities and Exchange Commission filings and reports, including the risks identified under the section captioned “Risk Factors” in our Quarterly Report on Form 10-Q filed on Aug. 15, 2011. We disclaim any obligation to update information contained in these forward-looking statements, whether as a result of new information, future events or otherwise.
# # #
